



Happy New Year!

On behalf of the COBO Technologies team

NEWS 2021



CRISPR Reagent Analysis

QC of your CRISPR Reagents using CRISPR-BIND

We are excited to launch [CRISPR-BIND](#), a Rapid and Highly Sensitive Tool to Characterise gRNA and CRISPR-Cas Interactions

CRISPR-BIND is built upon an entirely electronic platform with several capabilities ranging from performing quality control of CRISPR-Cas complexes and gRNA to optimizing CRISPR designs. Powered by Cardea's CRISPR-Chip™, a chipset that combines CRISPR-Cas molecules with graphene-based Biology-gated Transistors ([Cardean Transistors](#)™).

CRISPR-BIND **speeds up your CRISPR quality control process** and reduces the risk of false positives. All without the need for labels or amplification.



CRISPR-BIND is developed by [CRISPR QC](#).

Partnership with Cardea Bio

COBO Technologies and Cardea Bio partner to bring solutions to challenges with the precision of Genome editing.

"[COBO Technologies](#) and [Cardea Bio](#) partner to bring solutions to challenges with the precision of Genome editing. The partners have agreed to co-develop and market a portfolio of **CRISPR QC products and services** for quality control (QC) of CRISPR research, agricultural, and pre-clinical programs. Over the longer-term,

the parties aim to develop a COBO branded QC device based on Cardea's **CRISPR-Chip™ QC technology** for use before and after genome-editing in the pre-clinical setting".

Read the full Press Release [here](#).

CRISPR InDel Profiling Platform (CIPP)

Identify and Quantify any type of InDels in your CRISPR Cells - Service Updates

We have added a **Primer Design-Validation and PCR Service** to our [CRISPR InDel Profiling Platform](#) - A full-service InDel profiling package is now available - just send your edited genomic DNA and we will take care of the rest!


- **Primers** are designed based on COBO's **optimized** primer design rules for homogeneous **PCR amplification**
- **Selected primer designs** are experimentally **validated** by PCR. **Specificity and efficacy** are determined by COBO's optimized capillary electrophoretic fragment analysis workflows

- **InDel profiles are identified and quantified** using COBO's proprietary InDel profiling software, [ProfileIt 2.0™](#)
- COBO's **InDel profiling** service makes it easy to identify and quantify any type of InDels up to 1000bs from any species. Sensitivity down to 0.1%.

ProfileIt 2.0

[ProfileIt 2.0](#) is our proprietary InDel profiling software, developed for detailed InDel analysis of FSA files from ABI instruments. A new updated version of ProfileIt 2.0 has just been launched to support InDel analysis of FSA files from ABI3730XL. ProfileIt 2.0 now supports FSA files from the following instruments: ABI3500, ABI3500XL and ABI3730XL.

Different licensing models are available. Please request more info using the contact link below.




Proteome Expression Analysis (PIPPR®)

Analyzing Proteome Changes in CRISPR cells.

Below you will see an overview of our powerful proteome expression analysis platform ([PIPPR](#)). Proteins of wildtype (WT) and treated cells, e.g. knock-out (KO) cells are extracted and digested followed by LC-MS/MS analysis using SWATH Acquisition. Differential expression is evaluated based on fold-change and p-value,

and affected pathways are analyzed to enable biological interpretation of results. Find more technical information [here](#).

PIPPR is used today to confirm expected changes and look for potential unexpected changes (like off-targets).



Publications / Webinars

1. Lubas M *et al.* (2020) Global proteome profiling of CRISPR/Cas9 induced insertions and deletions. Full technote [here](#).
2. Bennett E *et al.* (2020) NDEL detection, the 'Achilles heel' of precise genome editing: a survey of methods for accurate profiling of gene editing induced indels. Read the full article [here](#).
3. Using SWATH®-MS to understand the impact on the Proteome of CRISPR gene editing. View Presentation [here](#).

**Team - Welcome our new BD
Specialist!**



Gerard Peralta Torres has a background in biotechnology from Universitat Autònoma de Barcelona (UAB) and moved to Denmark to pursue its master's degree in Bioentrepreneurship and Business Administration as part of the Biobusiness and Innovation Platform (BBIP) at Copenhagen Business School in

collaboration with Copenhagen University.

Joining COBO Technologies after having worked as a Competitive Intelligence student assistant at LEO Pharma and having collaborated closely with the LEO Pharma Open Innovation team evaluating the different R&D collaboration models in Pharma.

Gerard will be responsible for the further development of our QC platforms for genome editing (InDel profiling, Proteome analysis and CRISPR-Chip).

Do you want to hear more about our products and services?

[Request more information here](#)

Do you want to sign up to our Newsletter?

[Sign up here](#)



Copyright © 2020 COBO Technologies, All rights reserved.

Our mailing address is:

sales@cobotechnologies.com

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).